Next Article in Journal
On the Role of Glutamate in Presynaptic Development: Possible Contributions of Presynaptic NMDA Receptors
Next Article in Special Issue
Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment
Previous Article in Journal
VGLUTs and Glutamate Synthesis—Focus on DRG Neurons and Pain
Previous Article in Special Issue
The Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian Cancer
Article Menu

Export Article

Open AccessArticle
Biomolecules 2015, 5(4), 3438-3447; doi:10.3390/biom5043438

Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma

1
Department of Biopharmaceutical Sciences, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA
2
Department of Pathology, University of Illinois at Chicago, 840 South Wood Street, Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Jürg Bähler
Received: 20 August 2015 / Revised: 2 November 2015 / Accepted: 30 November 2015 / Published: 3 December 2015
(This article belongs to the Special Issue Signal Transduction Pathways in Gynecologic Malignancies)
View Full-Text   |   Download PDF [5214 KB, uploaded 3 December 2015]   |  

Abstract

Fallopian adenocarcinoma is a rare malignancy arising in the epithelium of the fallopian tube. Fallopian tube epithelium has been proposed as a tissue origin for high-grade serous ovarian carcinoma, the deadliest gynecologic malignancy. Given the commonalities in dissemination and treatment of these malignancies, we contemplated the possibility of similar patterns of gene expression underlying their progression. To reveal potential similarities or differences in the gene expression of fallopian adenocarcinoma and high-grade serous ovarian carcinoma, we tested expression of the fractalkine receptor (CX3CR1) and its ligand, fractalkine (CX3CL1), in the specimens of normal and pathologic fallopian tube using immunohistochemistry. Our data show that CX3CR1 is expressed in the normal, cancer adjacent normal, inflammatory, and malignant fallopian epithelium. CX3CL1 was expressed only by the normal and cancer adjacent normal fallopian tube epithelium; its expression was largely lost in the inflammatory and malignant fallopian epithelium. In opposite, both CX3CR1 and CX3CL1 are expressed in high-grade serous ovarian carcinoma. These findings are consistent with an idea that fallopian adenocarcinoma and high-grade serous ovarian carcinoma, although currently thought to arise from the same organ, may not share similar molecular characteristics. View Full-Text
Keywords: fractalkine; fractalkine receptor; fallopian carcinoma; ovarian carcinoma fractalkine; fractalkine receptor; fallopian carcinoma; ovarian carcinoma
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Gurler, H.; Macias, V.; Kajdacsy-Balla, A.A.; Barbolina, M.V. Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma. Biomolecules 2015, 5, 3438-3447.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top